Non-peptidic, Non-prenylic Bisubstrate Farnesyltransferase Inhibitors, 4. Effect on Farnesyltransferase Inhibitory Activity of Conformational Restrictions in the Central Group
Non-peptidic, non-prenylic bisubstrate farnesyltransferase inhibitors. Part 3: structural requirements of the central moiety for farnesyltransferase inhibitory activity
作者:Martin Schlitzer、Markus Böhm、Isabel Sattler
DOI:10.1016/s0968-0896(00)00173-5
日期:2000.10
we have described non-peptidic, non-prenylic bisubstrateanalogues as a novel type of farnesyltransferaseinhibitor composed of a farnesyl-mimetic, a linker and an AAX-peptidomimetic substructure. With this study, we showed that the amide function connecting the farnesyl-mimetic and the linking substructures of our inhibitors is crucial for their activity. We suggest that the amide is bound to the essential
Provided is a method for preparing a sugar chain, including: a labeling step of adding a labeling reagent to a sugar chain-containing sample which contains a sugar chain to obtain a labeled product containing a labeled substance of the sugar chain, in which a reaction environment of the labeling reagent and the sugar chain contains water in the labeling step.
METHOD, KIT AND DEVICE FOR PREPARING GLYCOPROTEIN SUGAR CHAIN
申请人:SUMITOMO BAKELITE CO., LTD.
公开号:US20180245115A1
公开(公告)日:2018-08-30
Provided is a method for preparing a glycoprotein sugar chain including: an isolation step of acting a sugar chain-isolating enzyme on a sample which contains a glycoprotein fixed to a solid phase in a container to obtain an isolated product which contains a sugar chain; and a labeling step of adding a labeling reagent to the isolated product in the container to obtain a labeled product which contains a labeled substance of the sugar chain.
structure-activity relationships of benzophenone-basedbisubstrateanaloguefarnesyltransferaseinhibitors yielded a bisubstrateanaloguefarnesyltransferaseinhibitor lacking any prenylic or peptidic substructures with nanomolar activity. This represents a considerable progress in comparison to those non-prenylic, non-peptidic bisubstrateanaloguefarnesyltransferaseinhibitors we have described before which